Ultragenyx Pharmaceutical Inc. (LON:0LIF)
United Kingdom · Delayed Price · Currency is GBP · Price in USD | Market Cap | 1.24B -44.5% |
| Revenue (ttm) | 549.86M +15.8% |
| Net Income | -394.69M |
| EPS | -3.89 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 27.46 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,718 |
| Open | 16.30 |
| Previous Close | 16.32 |
| Day's Range | 15.55 - 16.39 |
| 52-Week Range | 12.87 - 41.50 |
| Beta | 0.35 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 3, 2026 |
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment... [Read more]
Financial Performance
In 2025, Ultragenyx Pharmaceutical's revenue was $673.00 million, an increase of 20.18% compared to the previous year's $560.00 million. Losses were -$575.00 million, 1.05% more than in 2024.
Financial numbers in USD Financial StatementsNews
Ultragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare Products Regulatory Agency (MHRA)
BASEL, Switzerland, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Ultragenyx (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialisation of novel therapies for rare and ultra-rare ...
Ultragenyx price target lowered to $22 from $32 at Citi
Citi lowered the firm’s price target on Ultragenyx (RARE) to $22 from $32 and keeps a Buy rating on the shares after updating the firm’s model to reflect Q3 earnings…
Ultragenyx price target lowered to $32 from $35 at Barclays
Barclays analyst Eliana Merle lowered the firm’s price target on Ultragenyx (RARE) to $32 from $35 and keeps an Overweight rating on the shares following the Q3 report. Published first…
Ultragenyx price target raised to $19 from $18 at TD Cowen
TD Cowen raised the firm’s price target on Ultragenyx (RARE) to $19 from $18 and keeps a Buy rating on the shares. The firm updated its model following the slight…
Ultragenyx price target raised to $22 from $20 at Morgan Stanley
Morgan Stanley analyst Maxwell Skor raised the firm’s price target on Ultragenyx (RARE) to $22 from $20 and keeps an Equal Weight rating on the shares.
Ultragenyx drops after terminating UX701 for Wilson disease
Shares of Ultragenyx (RARE) are moving lower after the company disclosed in its earnings release that it is terminating UX701 for Wilson disease based on not achieving study goals. It…
Ultragenyx price target lowered to $22 from $25 at Wedbush
Wedbush lowered the firm’s price target on Ultragenyx (RARE) to $22 from $25 and keeps a Neutral rating on the shares. The firm notes the company reported a Q3 miss…
Ultragenyx price target lowered to $34 from $39 at Canaccord
Canaccord lowered the firm’s price target on Ultragenyx (RARE) to $34 from $39 and keeps a Buy rating on the shares. The firm said they reported 3Q26 earnings, and more…
Ultragenyx price target raised to $19 from $18 at Wells Fargo
Wells Fargo analyst Benjamin Burnett raised the firm’s price target on Ultragenyx (RARE) to $19 from $18 and keeps an Equal Weight rating on the shares. The firm likes the…
Ultragenyx price target lowered to $17 from $19 at Goldman Sachs
Goldman Sachs lowered the firm’s price target on Ultragenyx (RARE) to $17 from $19 and keeps a Neutral rating on the shares following the Q3 results. Goldman is focused on…
Ultragenyx Pharmaceutical Earnings Call Transcript: Q3 2026
Two new gene-therapy approvals broadened the portfolio, while GTX-102 and UX701 discontinuations drove major cost reductions. Management reaffirmed 2027 profitability, supported by portfolio growth, launches and ~$350 million in non-dilutive PRV proceeds.
Ultragenyx Pharmaceutical Earnings release: Q3 2026
Ultragenyx Pharmaceutical released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
Ultragenyx Pharmaceutical Quarterly report: Q3 2026
Ultragenyx Pharmaceutical has published its Q3 2026 quarterly earnings report on November 3, 2026.
Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027
Third quarter total revenue of $173 million, CRYSVITA® revenue of $109 million and DOJOLVI® revenue of $30 million GENGLYCOS™ and FAYUVI™ BLAs approved by FDA in the third quarter Two Priority Review ...
Ultragenyx Pharmaceutical Slides: Corporate presentation
Ultragenyx Pharmaceutical has posted slides in relation to its latest quarterly earnings report, which was published on November 3, 2026.
Ultragenyx to Host Conference Call for Third Quarter 2026 Financial Results and Corporate Update
NOVATO, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for seri...
Ultragenyx initiated with a Neutral at UBS
UBS initiated coverage of Ultragenyx (RARE) with a Neutral rating and $16 price target Two recent approvals, Fayuvi for MPSIIIA and Genglycos for GSD1a, reinforce the company’s ability to develop…
Ultragenyx to sell Rare Pediatric Disease PRV for $203M
Ultragenyx (RARE) announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher, or PRV, for $203M. Ultragenyx received the PRV upon FDA…
Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 Million
Agreement marks the Company's second PRV sale within one week, following the previously announced GENGLYCOS™ PRV transaction Agreement marks the Company's second PRV sale within one week, following th...
Ultragenyx Pharmaceutical Slides: Corporate presentation
Ultragenyx Pharmaceutical has posted slides in relation to its latest quarterly earnings report, which was published on October 14, 2026.
Ultragenyx to sell Rare Pediatric Disease Priority Review Voucher for $210M
Ultragenyx (RARE) announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher, or PRV, for $210M. Ultragenyx received the PRV upon FDA…
Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
NOVATO, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priorit...
Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A)
BASEL, Switzerland, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Today Ultragenyx announced that the European Medicines Agency (EMA) has validated the Company's Marketing Authorisation Application (MAA) for its ...
Ultragenyx price target raised to $18 from $16 at Evercore ISI
Evercore ISI raised the firm’s price target on Ultragenyx (RARE) to $18 from $16 and keeps an In Line rating on the shares.
Ultragenyx price target raised to $35 from $32 at Barclays
Barclays raised the firm’s price target on Ultragenyx (RARE) to $35 from $32 and keeps an Overweight rating on the shares following FDA approval of Fayuvi. The Angelman miss hurt…